Gilead’s ‘Truvada’ positioned at top in domestic HIV treatment market
The Gilead Sciences’ HIV therapy, Truvada, was observed to maintain the top position in the domestic HIV market.
According to the IMS Health DATA on the 8th, the Truvada backbone treatment’s market share in the domestic HIV market was 59.0% increased approximately by 9.1%, becoming the top in t...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
